Reimbursement Scheme Ontozry® (12.5mg/25mg, 50 mg, 100 mg, 150mg)
The health insurer does not fully reimburse ONTOZRY® (12.5mg/25mg, 50 mg, 100 mg, 150mg). The producer of this medicine has...
Reimbursement Scheme Jardiance® (empagliflozin)10 mg for patients with HFpEF (Ejection fraction>40%)
The health insurer does not yet fully reimburse Jardiance (Empagliflozin)® 10 mg for the treatment of HFpEF (Ejection fraction...
Extension to TerugBetaalRegeling Acecort®
Recently also Acecort® 2 and 3 mg tablets have been registered. The health insurer will not reimburse the cost in full. The...
Renewal reimbursement scheme Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine HCI) 5 mg
The Reimbursement Solution TerugBetaalRegeling (TBR) of Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine...
Termination TerugBetaalRegeling Tecfidera®
As of December 1, 2021, a Personal Contribution for Tecfidera is no longer required. Health insurers will once again fully...
Select your medicine
- Acecort®
- Adempas®
- Adhesa®
- Broxil®
- Cholestagel®
- Cresemba®
- Elvanse®
- Fludrace®
- Forxiga® - Diabetes
- Forxiga® - HFpEF
- Intuniv®
- Isturisa®
- Jardiance® - HF
- Jardiance® - Chronic Kidney Disease
- Kesimpta®
- Lokelma®
- Metoject Pen®
- Ontozry®
- Plenadren®
- Signifor®
- Uptravi®
- Veltassa ®
- Xigduo®
- Zeposia®
- Latest updates on Medicines
Check your medicine expenses
Quickly check the maximum contribution you have to pay for your medicine